Refractory Follicular Lymphoma
Oncology
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
5 drugs in development·3 companies·10 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| Liso-cel | BRISTOL MYERS SQUIBB CO (BMY) |
Phase 2(2)
Phase 1(1)
| Drug | Company |
|---|---|
| tazemetostat | Epizyme, Inc. (EPZM) |
Phase 4(1)
Compare drugs
Frequently asked questions
How many drugs are in development for Refractory Follicular Lymphoma?
BioSniper tracks 5 drugs in development for Refractory Follicular Lymphoma across 3 companies.
How many clinical trials target Refractory Follicular Lymphoma?
There are 10 clinical trials targeting Refractory Follicular Lymphoma tracked by BioSniper.
What is the prevalence of Refractory Follicular Lymphoma?
The estimated prevalence of Refractory Follicular Lymphoma is approximately 56.0 per 100,000 population.
Deep-dive into Refractory Follicular Lymphoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis